Relationship Between Serum Lipid Level and Colorectal Cancer: a Systemic Review and Meta-analysis

Overview

Journal BMJ Open

Specialty General Medicine

Date 2022 Jun 22

PMID 35732386

Authors

Zhenpeng Yang

Huazhen Tang

Shuai Lu

Xibo Sun

Benqiang Rao

Affiliations

Soon will be listed here.

Abstract

Objective: Investigative studies report contradictory results of the relationship between serum lipid levels and the risk of colorectal cancer (CRC). We conducted a meta-analysis of prospective published studies to clarify the relationship between serum lipid and CRC risk.

Design: Systematic review and meta-analysis.

Data Sources: PubMed and Embase from inception until December 2020.

Eligibility Criteria: We considered prospective cohort and case-control studies that evaluated differences in serum lipid levels with the risk of developing CRC.

Data Extraction And Synthesis: Two independent reviewers screened and included the studies using standardised electronic data extraction forms. The relative risks of the studies were combined with random-effect and fixed-effect models and were analysed for heterogeneity, publication bias and sensitivity.

Results: Twenty-four prospective studies, including 4 224 317 individuals with 29 499 CRC cases, were included in the meta-analysis. The total pooled risk ratio (RR) for high vs low concentrations of triglyceride (TG) concentrations was reported at 1.21 (95% CI 1.09 to 1.34; I=46.8%), total cholesterol (TC) was at 1.15 (95% CI 1.08 to 1.22; I=36.8%), high-density lipoprotein cholesterol (HDL-C) was 0.86 (95% CI 0.77 to 0.97; I=28.8%) and low-density lipoprotein cholesterol (LDL-C) was observed at 1.03 (95% CI 0.75 to 1.41; I=69.4%).

Conclusions: This meta-analysis shows that high levels of serum TG and TC are positively correlated with the incidence rate of CRC, while high levels of serum HDL-C are negatively correlated with CRC incidence rate. Furthermore, no association was found between LDL-C and the risk of developing CRC. Nevertheless, the heterogeneity brought about by comparative methods, demographic differences and pathological differences between the research subjects limits the effectiveness of the overall pooled results.

Citing Articles

Low-Density Lipoprotein (LDL) is Associated with Earlier Progression in Synchronous Metastatic Colorectal Cancer Treated without Curative Intent.

Akkus E, Oksuz N, Utkan G J Gastrointest Cancer. 2025; 56(1):58.

PMID: 39907838 DOI: 10.1007/s12029-025-01166-3.

Lipid levels and insulin resistance markers in patients with colorectal cancer: Propensity score matching analysis.

Hu R, Yan D, Zhang K, Zhang D, Cui X, Jiang X World J Gastrointest Oncol. 2025; 17(1):100204.

PMID: 39817133 PMC: 11664609. DOI: 10.4251/wjgo.v17.i1.100204.

Impact of serum lipid on recurrence of uterine fibroids: a single center retrospective study.

Ma Y, Weng J, Zhu Y BMC Womens Health. 2024; 24(1):677.

PMID: 39741237 PMC: 11686845. DOI: 10.1186/s12905-024-03530-0.

Comprehensive Mendelian randomization analysis of low-density lipoprotein cholesterol and multiple cancers.

Liang H, Tang C, Sun Y, Wang M, Tong T, Gao Q Discov Oncol. 2024; 15(1):798.

PMID: 39692937 PMC: 11655734. DOI: 10.1007/s12672-024-01684-9.

Associations of blood lipids and LDL cholesterol lowering drug-targets with colorectal cancer risk: a Mendelian randomisation study.

Chan W, Liu L, Bouras E, Zuber V, Wen W, Long J Br J Cancer. 2024; 132(1):103-110.

PMID: 39580580 PMC: 11723917. DOI: 10.1038/s41416-024-02900-7.

References

Yao X, Tian Z . Dyslipidemia and colorectal cancer risk: a meta-analysis of prospective studies. Cancer Causes Control. 2014; 26(2):257-268. DOI: 10.1007/s10552-014-0507-y. View

Li X, Chen H, Wang G, Feng X, Lyu Z, Wei L . Metabolic Syndrome Components and the Risk of Colorectal Cancer: A Population-Based Prospective Study in Chinese Men. Front Oncol. 2019; 9:1047. PMC: 6811600. DOI: 10.3389/fonc.2019.01047. View

Gaard M, Tretli S, Urdal P . Blood lipid and lipoprotein levels and the risk of cancer of the colon and rectum. A prospective study of 62,173 Norwegian men and women. Scand J Gastroenterol. 1997; 32(2):162-8. DOI: 10.3109/00365529709000187. View

van Duijnhoven F, Bueno-de-Mesquita H, Calligaro M, Jenab M, Pischon T, Jansen E . Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition. Gut. 2011; 60(8):1094-102. DOI: 10.1136/gut.2010.225011. View

Borena W, Stocks T, Jonsson H, Strohmaier S, Nagel G, Bjorge T . Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study. Cancer Causes Control. 2010; 22(2):291-9. DOI: 10.1007/s10552-010-9697-0. View

Cai X, Gu D, Chen M, Liu L, Chen D, Lu L . The effect of the primary tumor location on the survival of colorectal cancer patients after radical surgery. Int J Med Sci. 2018; 15(14):1640-1647. PMC: 6299419. DOI: 10.7150/ijms.27834. View

Vallejo-Vaz A, Fayyad R, Boekholdt S, Hovingh G, Kastelein J, Melamed S . Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. Circulation. 2018; 138(8):770-781. DOI: 10.1161/CIRCULATIONAHA.117.032318. View

Siegel R, Miller K, Fedewa S, Ahnen D, Meester R, Barzi A . Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017; 67(3):177-193. DOI: 10.3322/caac.21395. View

Gazzola K, Reeskamp L, van den Born B . Ethnicity, lipids and cardiovascular disease. Curr Opin Lipidol. 2017; 28(3):225-230. DOI: 10.1097/MOL.0000000000000412. View

10.

Strohmaier S, Edlinger M, Manjer J, Stocks T, Bjorge T, Borena W . Total serum cholesterol and cancer incidence in the Metabolic syndrome and Cancer Project (Me-Can). PLoS One. 2013; 8(1):e54242. PMC: 3553083. DOI: 10.1371/journal.pone.0054242. View

11.

Hamling J, Lee P, Weitkunat R, Ambuhl M . Facilitating meta-analyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease category. Stat Med. 2007; 27(7):954-70. DOI: 10.1002/sim.3013. View

12.

Kitahara C, Berrington de Gonzalez A, Freedman N, Huxley R, Mok Y, Jee S . Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol. 2011; 29(12):1592-8. PMC: 3082977. DOI: 10.1200/JCO.2010.31.5200. View

13.

Ahmed R, Schmitz K, Anderson K, Rosamond W, Folsom A . The metabolic syndrome and risk of incident colorectal cancer. Cancer. 2006; 107(1):28-36. DOI: 10.1002/cncr.21950. View

14.

Yang W, Bai Y, Xiong Y, Zhang J, Chen S, Zheng X . Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism. Nature. 2016; 531(7596):651-5. PMC: 4851431. DOI: 10.1038/nature17412. View

15.

Katzke V, Sookthai D, Johnson T, Kuhn T, Kaaks R . Blood lipids and lipoproteins in relation to incidence and mortality risks for CVD and cancer in the prospective EPIC-Heidelberg cohort. BMC Med. 2017; 15(1):218. PMC: 5735858. DOI: 10.1186/s12916-017-0976-4. View

16.

Iso H, Ikeda A, Inoue M, Sato S, Tsugane S . Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts. Int J Cancer. 2009; 125(11):2679-86. DOI: 10.1002/ijc.24668. View

17.

Schoen R, Tangen C, Kuller L, Burke G, Cushman M, Tracy R . Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst. 1999; 91(13):1147-54. DOI: 10.1093/jnci/91.13.1147. View

18.

Charlton F, Tooher J, Rye K, Hennessy A . Cardiovascular risk, lipids and pregnancy: preeclampsia and the risk of later life cardiovascular disease. Heart Lung Circ. 2013; 23(3):203-12. DOI: 10.1016/j.hlc.2013.10.087. View

19.

Zhao X, Zhang H, Sun D, Xu R, Guo Y, Sun J . Relation of oxidized-low-density lipoprotein and high-density lipoprotein subfractions in non-treated patients with coronary artery disease. Prostaglandins Other Lipid Mediat. 2019; 144:106345. DOI: 10.1016/j.prostaglandins.2019.106345. View

20.

Peng F, Hu D, Lin X, Chen G, Liang B, Chen Y . An in-depth prognostic analysis of baseline blood lipids in predicting postoperative colorectal cancer mortality: The FIESTA study. Cancer Epidemiol. 2018; 52:148-157. DOI: 10.1016/j.canep.2018.01.001. View